|
Oct 9
|
PTC Therapeutics Inc (PTCT) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
|
|
Oct 9
|
PTC Therapeutics (PTCT) Surges 16.5%: Is This an Indication of Further Gains?
|
|
Oct 9
|
PTCT Stock Rises on Positive Updates on Friedreich Ataxia Program
|
|
Oct 8
|
Sector Update: Health Care Stocks Rise Late Afternoon
|
|
Oct 8
|
PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program
|
|
Oct 4
|
3 Top Stocks That Could Still Rocket Higher in 2024
|
|
Oct 1
|
PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients
|
|
Oct 1
|
5 FDA decisions to watch in the fourth quarter
|
|
Sep 26
|
FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program
|
|
Aug 26
|
PTC Therapeutics Has Upside Potential With Multiple Upcoming Catalysts, UBS Says
|
|
Aug 1
|
Crinetics Pharmaceuticals, Inc. (CRNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
|
|
Jul 30
|
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA
|
|
Jul 25
|
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results
|
|
Jul 25
|
Will PTC Therapeutics (PTCT) Report Negative Q2 Earnings? What You Should Know
|
|
Jun 28
|
PTC's Journey Of 'Twist And Doubt' Continues With Another Rejection; Shares Tumble
|
|
Jun 28
|
PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar
|
|
Jun 28
|
CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review
|
|
Jun 24
|
PTC Therapeutics (PTCT) Soars 9.7%: Is Further Upside Left in the Stock?
|
|
Jun 20
|
FDA lifts hold on PTC Huntington’s disease trial
|
|
Jun 20
|
Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients
|